基于胆红素、国际标准化比率探讨自身免疫性肝炎肝移植时机的研究

Abstract
Figure/Table
References
Related Citation (1)

Download: PDF (4051 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective Application of bilirubin and international standardized ratio to predict the timing of liver transplantation in autoimmune hepatitis (AIH). Methods This was a retrospective cohort study conducted in our hospital from January 2018 to October 2022, and 52 AIH patients were selected as the research objects. The baseline international normalized ratio (INR), the change of INR and the change of total bilirubin within 3 days after starting corticosteroid treatment were recorded on the first day (D0) and the third day (D3) to calculate the SURFASA score. The performance of SURFASA in predicting the response to corticosteroid therapy was evaluated by the area under the operator characteristic curve (AUC) of subjects. Results Of the 52 patients, 38(73.1%) responded to corticosteroids, 10(19.2%) received liver transplantation, and 4(7.7%) died of infectious complications. SURFASA score of respondents[-4.40 (-4.82, -3.82)] was significantly lower than that of non-responders [-1.83 (-2.37, -1.84)]. INR (D3) [OR=6.85; 95%CI 2.23-7.06; P<0.001)] and SURFASA [OR=6.97; 95%CI 1.59-30.46; P<0.001) ] was independently related to corticosteroid unresponsiveness. SURFASA score (AUC=0.96, 95%CI 0.92-1.00) had excellent performance in predicting treatment response. The sensitivity, specificity, PPV and NPV of excluding corticosteroid response with a score higher than -2.6 were 85.7%, 100%, 100% and 95%, respectively. Conclusions SURFASA score has the highest AUC in early identification of unresponsiveness to corticosteroids in patients with AIH, indicating that it may be a valuable tool for rapid evaluation of liver transplantation.

Key words： bilirubin international standardized ratio autoimmune hepatitis liver transplantation

Received: 26 June 2023

PACS:

R617

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LI Xiaoning
	TIAN Min
	LIN Ting
	JING Hua
	XING Binyu
	SHEN Cunyi
	ZHANG Huilin
	SU Juan

Cite this article:

LI Xiaoning,TIAN Min,LIN Ting等. A study on the timing of liver transplantation in autoimmune hepatitis based on bilirubin and international standardized ratios[J]. HuNan ShiFan DaXue XueBao(YiXueBan), 2024, 21(3): 110-114.

URL:

http://yxb.hunnu.edu.cn/EN/ OR http://yxb.hunnu.edu.cn/EN/Y2024/V21/I3/110

[1] 胡明礼, 王绮夏, 马雄. 自身免疫性肝炎发病机制进展与临床干预新靶点[J]. 临床肝胆病杂志, 2022, 38(4): 743-747.
[2] WANG G, TANAKA A, ZHAO H, et al.The Asian Pacific Association for the Study of the Liver clinical practice guidance: the diagnosis and management of patients with autoimmune hepatitis[J]. Hepatol Int, 2021, 15(2): 223-257.
[3] DE MARTIN E, COILLY A, CHAZOUILLÈRES O, et al. Early liver transplantation for corticosteroid non-responders with acute severe autoimmune hepatitis: the SURFASA score[J]. J Hepatol, 2021, 74(6): 1325-1334.
[4] RAHIM M N, MIQUEL R, HENEGHAN M A.Approach to the patient with acute severe autoimmune hepatitis[J]. JHEP Rep, 2020, 2(6): 100149.
[5] RAHIM M N, LIBERAL R, MIQUEL R, et al.Acute severe autoimmune hepatitis: corticosteroids or liver transplantation?[J]. Liver Transpl, 2019, 25(6): 946-959.
[6] LIBERAL R, MACEDO G.Acute severe autoimmune hepatitis-timing for steroids and role of other immunosuppressive agents[J]. J Hepatol, 2021, 75(2): 494-495.
[7] BIEWENGA M, VERHELST X, BAVEN-PRONK M, et al. Aminotransferases During Treatment Predict Long-Term Survival in Patients With Autoimmune Hepatitis Type 1: A Landmark Analysis[J]. Clin Gastroenterol Hepatol, 2022, 20(8): 1776-1783. e4.
[8] SHARMA S, AGARWAL S, GOPI S, et al.Determinants of outcomes in autoimmune hepatitis presenting as acute on chronic liver failure without extrahepatic organ dysfunction upon treatment with steroids[J]. J Clin Exp Hepatol, 2021, 11(2): 171-180.
[9] YANG M, PENG B, ZHUANG Q, et al.Models to predict the short-term survival of acute-on-chronic liver failure patients following liver transplantation[J]. BMC Gastroenterol, 2022, 22(1): 80.
[10] LIN S, HALL A, KUMAR R, et al.Validation of the SURFASA score to define steroid responsiveness in patients with acute autoimmune hepatitis[J]. J Hepatol, 2022, 76(2): 485-487.
[11] GRANITO A, MURATORI P, MURATORI L.Acute-on-chronic liver failure: a complex clinical entity in patients with autoimmune hepatitis[J]. J Hepatol, 2021, 75(6): 1503-1505.
[12] OLIVAS I, COBREROS M, LONDOÑO M C, et al. Budesonide in the first line treatment of patients with autoimmune hepatitis[J]. Gastroenterol Hepatol, 2022, 45(7): 561-570.
[13] ZACHOU K, ARVANITI P, AZARIADIS K, et al.Prompt initiation of high-dose iv corticosteroids seems to prevent progression to liver failure in patients with original acute severe autoimmune hepatitis[J]. Hepatol Res, 2019, 49(1): 96-104.
[14] NOGUCHI F, CHU P, YOSHIDA A, et al. Early dynamics of MELD scores predict corticosteroid responsiveness to severe acute-onset autoimmune hepatitis[J]. Clin Gastroenterol Hepatol, 2022, 20(11): 2641-2643. e3.
[15] SHARMA S, AGARWAL S, SARAYA A, et al.Identifying the early predictors of non-response to steroids in patients with flare of autoimmune hepatitis causing acute-on-chronic liver failure[J]. Hepatol Int, 2023: 1-11.